Auris Medical Holding (EARS) Reports Q3 Loss of $0.14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Auris Medical Reports Third Quarter 2018 Financial Results and Provides Business Update
November 15, 2018 6:45 AM ESTPositive outcomes from second Phase 1 trial with intranasal betahistine Further evidence for betahistine's preventive effects in antipsychotic-induced weight gain Progressing intranasal betahistine program towards proof-of-concept studies Partnering process initiated for AM-111 program Sonsuvi® accepted as brand name for AM-111
Zug, Switzerland, November 15, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address... More
